CAJ | 학술논문

目的：研究吡格列酮对膀胱癌患者机体炎症因子的抑制作用。方法连续选择2012年2月～2014年2月来湖北医药学院附属东风总医院并诊断为膀胱癌的患者共100例，随机将其分为试验组和对照组各50例，所有患者根据病理分型和分期选择手术、化疗等方案，试验组患者同时接受吡格列酮治疗，15 mg／d×12周；对照组接受常规的治疗方案。对比分析两组患者治疗前后的炎症因子的表达水平，高敏 C 反应蛋白（hs-CRP），肿瘤坏死因子α（TNF-α），白介素（IL-6）以及HOMA-IR 水平，MCP-1和 MIP-1因子的水平的差异性。结果治疗后两组患者的 hs-CRP，TNF-α和 IL-6水平均降低，差异均有统计学意义（P ＜0.05），且试验组降低的更明显，差异均有统计学意义（P ＜0.05）。两组患者的 HOMA-IR， MCP-1和 MIP-1水平均降低，差异均有统计学意义（P ＜0.05），且试验组降低的更明显，差异均有统计学意义（P ＜0.05）。两组患者不良反应率的比较，差异无统计学意义（P ＞0.05）。结论吡格列酮可能通过降低膀胱癌患者的炎症因子如 hs-CRP，TNF-α，IL-6，HOMA-IR，MCP-1和 MIP-1水平提高临床效果，改善预后。
목적：연구필격렬동대방광암환자궤체염증인자적억제작용。방법련속선택2012년2월～2014년2월래호북의약학원부속동풍총의원병진단위방광암적환자공100례，수궤장기분위시험조화대조조각50례，소유환자근거병리분형화분기선택수술、화료등방안，시험조환자동시접수필격렬동치료，15 mg／d×12주；대조조접수상규적치료방안。대비분석량조환자치료전후적염증인자적표체수평，고민 C 반응단백（hs-CRP），종류배사인자α（TNF-α），백개소（IL-6）이급HOMA-IR 수평，MCP-1화 MIP-1인자적수평적차이성。결과치료후량조환자적 hs-CRP，TNF-α화 IL-6수평균강저，차이균유통계학의의（P ＜0.05），차시험조강저적경명현，차 이 균 유 통 계 학의의（P ＜0.05）。량조환자적 HOMA-IR， MCP-1화 MIP-1수평균강저，차이균유통계학의의（P ＜0.05），차시험조강저적경명현，차이균유통계학의의（P ＜0.05）。량조환자불량반응솔적비교，차이무통계학의의（P ＞0.05）。결론필격렬동가능통과강저방광암환자적염증인자여 hs-CRP，TNF-α，IL-6，HOMA-IR，MCP-1화 MIP-1수평제고림상효과，개선예후。
Objecitve To study the inhibitory effect of pioglitazone on inflammation factors in patients with bladder cancer. Methods A total of 100 consecutives diagnosed as bladder cancer from Februray 2013 to Februray 2014 were individed ran-domly into experiment and control groups and each of 50 cases.All patients received the appropriate operation or chemother-apeutic regimens,and the patients in experiment group received pioglitazone (15 mg/d×12 weeks)at the same time.Then to compare expression differences of high-sensitive C reactive protein (hs-CRP),tumor necrosis factor alpha (TNF-alpha),in-terleukin (IL-6)and HOMA-IR,MCP-1,MIP-1 levels.Results The levels of hs-CRP,TNF-αand IL-6 in the two groups af-ter treatment were all lower (P <0.05),and in experiment groups they were significantly lower than control group (P <0.05).The levels of HOMA-IR,MCP-1 and MIP-1 in the two groups after treatment were all lower (P <0.05),and in ex-periment groups they were significantly lower than control group(P <0.05).The complication rate in the two groups were no statistical difference (P >0.05).Conclusion Pioglitazone could improve clinical effect and prognosis by lowing inflam-mation factors including hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1 and MIP-1 in patients with bladder cancer.